APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ustekinumab Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Ustekinumab Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025185 pages

Choose your research edition.

Industry ResearchUstekinumab Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Ustekinumab Biosimilars Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Ustekinumab Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ustekinumab Biosimilars Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ustekinumab Biosimilars Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Ustekinumab Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Ustekinumab Biosimilars include Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, Celltrion, Qyuns Therapeutics, Bio-Thera Solutions and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ustekinumab Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ustekinumab Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ustekinumab Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ustekinumab Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Ustekinumab Biosimilars Segment by Company

Teva

Amgen

Samsung Bioepis

Sandoz

Biocon Biologics

Celltrion

Qyuns Therapeutics

Bio-Thera Solutions

Huadong Medicine

Ustekinumab Biosimilars Segment by Type

Subcutaneous Injection

Intravenous Infusion

Ustekinumab Biosimilars Segment by Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Psoriatic Arthritis

Other

Ustekinumab Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ustekinumab Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ustekinumab Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ustekinumab Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ustekinumab Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Ustekinumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Ustekinumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Ustekinumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Ustekinumab Biosimilars Industry Trends Table 2. Ustekinumab Biosimilars Industry Drivers Table 3. Ustekinumab Biosimilars Industry Opportunities and Challenges Table 4. Ustekinumab Biosimilars Industry Restraints Table 5. Global Ustekinumab Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Ustekinumab Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Ustekinumab Biosimilars Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Ustekinumab Biosimilars Sales Market Share by Manufacturers Table 9. Global Ustekinumab Biosimilars Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Ustekinumab Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Ustekinumab Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Ustekinumab Biosimilars Manufacturers, Product Type & Application Table 13. Global Ustekinumab Biosimilars Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Ustekinumab Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Subcutaneous Injection Table 17. Major Manufacturers of Intravenous Infusion Table 18. Global Ustekinumab Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 20. Global Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 21. Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2026) Table 22. Global Ustekinumab Biosimilars Sales Market Share by Type (2027-2032) Table 23. Global Ustekinumab Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Ustekinumab Biosimilars Revenue by Type (2021-2026) & (K Units) Table 25. Global Ustekinumab Biosimilars Revenue by Type (2027-2032) & (K Units) Table 26. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2026) Table 27. Global Ustekinumab Biosimilars Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Crohn's Disease Table 29. Major Manufacturers of Ulcerative Colitis Table 30. Major Manufacturers of Plaque Psoriasis Table 31. Major Manufacturers of Psoriatic Arthritis Table 32. Major Manufacturers of Other Table 33. Global Ustekinumab Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 35. Global Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 36. Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2026) Table 37. Global Ustekinumab Biosimilars Sales Market Share by Application (2027-2032) Table 38. Global Ustekinumab Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Ustekinumab Biosimilars Revenue by Application (2021-2026) & (K Units) Table 40. Global Ustekinumab Biosimilars Revenue by Application (2027-2032) & (K Units) Table 41. Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2026) Table 42. Global Ustekinumab Biosimilars Revenue Market Share by Application (2027-2032) Table 43. Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Ustekinumab Biosimilars Sales by Region (2021-2026) & (K Units) Table 45. Global Ustekinumab Biosimilars Sales Market Share by Region (2021-2026) Table 46. Global Ustekinumab Biosimilars Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Ustekinumab Biosimilars Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 50. North America Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 51. Europe Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 53. Europe Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 60. Global Ustekinumab Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Ustekinumab Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Ustekinumab Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Ustekinumab Biosimilars Revenue Market Share by Region (2021-2026) Table 64. Global Ustekinumab Biosimilars Revenue Market Share by Region (2027-2032) Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Ustekinumab Biosimilars Product Portfolio Table 69. Teva Recent Development Table 70. Amgen Company Information Table 71. Amgen Business Overview Table 72. Amgen Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Amgen Ustekinumab Biosimilars Product Portfolio Table 74. Amgen Recent Development Table 75. Samsung Bioepis Company Information Table 76. Samsung Bioepis Business Overview Table 77. Samsung Bioepis Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Samsung Bioepis Ustekinumab Biosimilars Product Portfolio Table 79. Samsung Bioepis Recent Development Table 80. Sandoz Company Information Table 81. Sandoz Business Overview Table 82. Sandoz Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sandoz Ustekinumab Biosimilars Product Portfolio Table 84. Sandoz Recent Development Table 85. Biocon Biologics Company Information Table 86. Biocon Biologics Business Overview Table 87. Biocon Biologics Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Biocon Biologics Ustekinumab Biosimilars Product Portfolio Table 89. Biocon Biologics Recent Development Table 90. Celltrion Company Information Table 91. Celltrion Business Overview Table 92. Celltrion Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Celltrion Ustekinumab Biosimilars Product Portfolio Table 94. Celltrion Recent Development Table 95. Qyuns Therapeutics Company Information Table 96. Qyuns Therapeutics Business Overview Table 97. Qyuns Therapeutics Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio Table 99. Qyuns Therapeutics Recent Development Table 100. Bio-Thera Solutions Company Information Table 101. Bio-Thera Solutions Business Overview Table 102. Bio-Thera Solutions Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio Table 104. Bio-Thera Solutions Recent Development Table 105. Huadong Medicine Company Information Table 106. Huadong Medicine Business Overview Table 107. Huadong Medicine Ustekinumab Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Huadong Medicine Ustekinumab Biosimilars Product Portfolio Table 109. Huadong Medicine Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Ustekinumab Biosimilars Distributors List Table 113. Ustekinumab Biosimilars Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Ustekinumab Biosimilars Product Image Figure 2. Global Ustekinumab Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ustekinumab Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Ustekinumab Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Ustekinumab Biosimilars Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Ustekinumab Biosimilars Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Subcutaneous Injection Image Figure 9. Intravenous Infusion Image Figure 10. Global Ustekinumab Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Ustekinumab Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2032) Figure 13. Global Ustekinumab Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Ustekinumab Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2032) Figure 16. Crohn's Disease Image Figure 17. Ulcerative Colitis Image Figure 18. Plaque Psoriasis Image Figure 19. Psoriatic Arthritis Image Figure 20. Other Image Figure 21. Global Ustekinumab Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Ustekinumab Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2032) Figure 24. Global Ustekinumab Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Ustekinumab Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2032) Figure 27. North America Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Ustekinumab Biosimilars Sales Market Share by Country (2021-2032) Figure 29. U.S. Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Ustekinumab Biosimilars Sales Market Share by Country (2021-2032) Figure 34. Germany Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Ustekinumab Biosimilars Sales Market Share by Country (2021-2032) Figure 41. China Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Ustekinumab Biosimilars Sales Market Share by Country (2021-2032) Figure 49. Brazil Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Ustekinumab Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Ustekinumab Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Ustekinumab Biosimilars Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Figure 60. North America Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Figure 62. Europe Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Ustekinumab Biosimilars Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Ustekinumab Biosimilars Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Injection
  • Intravenous Infusion
Applications
  • Crohn's Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Teva
  • Amgen
  • Samsung Bioepis
  • Sandoz
  • Biocon Biologics
  • Celltrion
  • Qyuns Therapeutics
  • Bio-Thera Solutions
  • Huadong Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ustekinumab Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ustekinumab Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Ustekinumab Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Ustekinumab Biosimilars Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Ustekinumab Biosimilars Market Dynamics
  1. 2.1 Ustekinumab Biosimilars Industry Trends
  2. 2.2 Ustekinumab Biosimilars Industry Drivers
  3. 2.3 Ustekinumab Biosimilars Industry Opportunities and Challenges
  4. 2.4 Ustekinumab Biosimilars Industry Restraints
3 Ustekinumab Biosimilars Market by Manufacturers
  1. 3.1 Global Ustekinumab Biosimilars Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Ustekinumab Biosimilars Sales by Manufacturers (2021-2026)
  3. 3.3 Global Ustekinumab Biosimilars Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Ustekinumab Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Ustekinumab Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Ustekinumab Biosimilars Manufacturers, Product Type & Application
  7. 3.7 Global Ustekinumab Biosimilars Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Ustekinumab Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Ustekinumab Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Ustekinumab Biosimilars Tier 1, Tier 2, and Tier 3
4 Ustekinumab Biosimilars Market by Type
  1. 4.1 Ustekinumab Biosimilars Type Introduction
  2. 4.1.1 Subcutaneous Injection
  3. 4.1.2 Intravenous Infusion
  4. 4.2 Global Ustekinumab Biosimilars Sales by Type
  5. 4.2.1 Global Ustekinumab Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Ustekinumab Biosimilars Sales by Type (2021-2032)
  7. 4.2.3 Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2032)
  8. 4.3 Global Ustekinumab Biosimilars Revenue by Type
  9. 4.3.1 Global Ustekinumab Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Ustekinumab Biosimilars Revenue by Type (2021-2032)
  11. 4.3.3 Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2032)
5 Ustekinumab Biosimilars Market by Application
  1. 5.1 Ustekinumab Biosimilars Application Introduction
  2. 5.1.1 Crohn's Disease
  3. 5.1.2 Ulcerative Colitis
  4. 5.1.3 Plaque Psoriasis
  5. 5.1.4 Psoriatic Arthritis
  6. 5.1.5 Other
  7. 5.2 Global Ustekinumab Biosimilars Sales by Application
  8. 5.2.1 Global Ustekinumab Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Ustekinumab Biosimilars Sales by Application (2021-2032)
  10. 5.2.3 Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2032)
  11. 5.3 Global Ustekinumab Biosimilars Revenue by Application
  12. 5.3.1 Global Ustekinumab Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Ustekinumab Biosimilars Revenue by Application (2021-2032)
  14. 5.3.3 Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2032)
6 Global Ustekinumab Biosimilars Sales by Region
  1. 6.1 Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ustekinumab Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Ustekinumab Biosimilars Sales by Region (2021-2026)
  4. 6.2.2 Global Ustekinumab Biosimilars Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Ustekinumab Biosimilars Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Ustekinumab Biosimilars Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Ustekinumab Biosimilars Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Ustekinumab Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Ustekinumab Biosimilars Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Ustekinumab Biosimilars Revenue by Region
  1. 7.1 Global Ustekinumab Biosimilars Revenue by Region
  2. 7.1.1 Global Ustekinumab Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Ustekinumab Biosimilars Revenue by Region (2021-2026)
  4. 7.1.3 Global Ustekinumab Biosimilars Revenue by Region (2027-2032)
  5. 7.1.4 Global Ustekinumab Biosimilars Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Ustekinumab Biosimilars Revenue (2021-2032)
  8. 7.2.2 North America Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Ustekinumab Biosimilars Revenue (2021-2032)
  11. 7.3.2 Europe Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Ustekinumab Biosimilars Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Ustekinumab Biosimilars Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Ustekinumab Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Ustekinumab Biosimilars Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Ustekinumab Biosimilars Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Samsung Bioepis
  14. 8.3.1 Samsung Bioepis Company Information
  15. 8.3.2 Samsung Bioepis Business Overview
  16. 8.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Bioepis Ustekinumab Biosimilars Product Portfolio
  18. 8.3.5 Samsung Bioepis Recent Developments
  19. 8.4 Sandoz
  20. 8.4.1 Sandoz Company Information
  21. 8.4.2 Sandoz Business Overview
  22. 8.4.3 Sandoz Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sandoz Ustekinumab Biosimilars Product Portfolio
  24. 8.4.5 Sandoz Recent Developments
  25. 8.5 Biocon Biologics
  26. 8.5.1 Biocon Biologics Company Information
  27. 8.5.2 Biocon Biologics Business Overview
  28. 8.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biocon Biologics Ustekinumab Biosimilars Product Portfolio
  30. 8.5.5 Biocon Biologics Recent Developments
  31. 8.6 Celltrion
  32. 8.6.1 Celltrion Company Information
  33. 8.6.2 Celltrion Business Overview
  34. 8.6.3 Celltrion Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Celltrion Ustekinumab Biosimilars Product Portfolio
  36. 8.6.5 Celltrion Recent Developments
  37. 8.7 Qyuns Therapeutics
  38. 8.7.1 Qyuns Therapeutics Company Information
  39. 8.7.2 Qyuns Therapeutics Business Overview
  40. 8.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio
  42. 8.7.5 Qyuns Therapeutics Recent Developments
  43. 8.8 Bio-Thera Solutions
  44. 8.8.1 Bio-Thera Solutions Company Information
  45. 8.8.2 Bio-Thera Solutions Business Overview
  46. 8.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio
  48. 8.8.5 Bio-Thera Solutions Recent Developments
  49. 8.9 Huadong Medicine
  50. 8.9.1 Huadong Medicine Company Information
  51. 8.9.2 Huadong Medicine Business Overview
  52. 8.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Huadong Medicine Ustekinumab Biosimilars Product Portfolio
  54. 8.9.5 Huadong Medicine Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ustekinumab Biosimilars Value Chain Analysis
  2. 9.1.1 Ustekinumab Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ustekinumab Biosimilars Production Mode & Process
  6. 9.2 Ustekinumab Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ustekinumab Biosimilars Distributors
  9. 9.2.3 Ustekinumab Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst